Department of Cardiology, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.
Department of Pharmaceutics, College of Pharmacy, Third Military Medical University (Army Medical University), Chongqing 400038, China.
Theranostics. 2021 Jul 25;11(17):8550-8569. doi: 10.7150/thno.61875. eCollection 2021.
Heart failure is a serious clinical and public health problem. Currently there is an unmet demand for effective therapies for heart failure. Herein we reported noninvasive inhalation delivery of nanotherapies to prevent heart failure. A reactive oxygen species (ROS)-scavenging material (TPCD) was synthesized, which was processed into antioxidative and anti-inflammatory nanoparticles (, TPCD NP). By decoration with a mitochondrial-targeting moiety, a multilevel targeting nanotherapy TTPCD NP was engineered. Pulmonary accumulation of inhaled TPCD NP and underlying mechanisms were examined in mice. efficacies of nanotherapies were evaluated in mice with doxorubicin (DOX)-induced cardiomyopathy. Further, an antioxidative, anti-inflammatory, and pro-resolving nanotherapy (, ATTPCD NP) was developed, by packaging a peptide Ac2-26. and efficacies of ATTPCD NP were also evaluated. TPCD NP alleviated DOX-induced oxidative stress and cell injury by internalization in cardiomyocytes and scavenging overproduced ROS. Inhaled TPCD NP can accumulate in the heart of mice by transport across the lung epithelial and endothelial barriers. Correspondingly, inhaled TPCD NP effectively inhibited DOX-induced heart failure in mice. TTPCD NP showed considerably enhanced heart targeting capability, cellular uptake efficiency, and mitochondrial localization capacity, thereby potentiating therapeutic effects. Notably, TPCD NP can serve as bioactive and ROS-responsive nanovehicles to achieve combination therapy with Ac2-26, affording further enhanced efficacies. Importantly, inhaled TPCD NP displayed good safety at a dose 5-fold higher than the efficacious dose. Inhalation delivery of nanoparticles is an effective, safe, and noninvasive strategy for targeted treatment of heart diseases. TPCD NP-based nanotherapies are promising drugs for heart failure and other acute/chronic heart diseases associated with oxidative stress.
心力衰竭是一个严重的临床和公共卫生问题。目前,心力衰竭的有效治疗方法仍存在未满足的需求。在此,我们报告了通过非侵入性吸入递送来预防心力衰竭的纳米疗法。我们合成了一种活性氧(ROS)清除材料(TPCD),并将其加工成抗氧化和抗炎纳米颗粒(TPCD NP)。通过修饰线粒体靶向部分,设计了一种多水平靶向纳米疗法 TTPCD NP。在小鼠中研究了吸入 TPCD NP 的肺部积累及其潜在机制。在多柔比星(DOX)诱导的心肌病小鼠中评估了纳米疗法的疗效。此外,还开发了一种抗氧化、抗炎和促解决的纳米疗法(ATTPCD NP),通过包装肽 Ac2-26。还评估了 ATTPCD NP 的疗效。TPCD NP 通过在心肌细胞内吞作用和清除过产生的 ROS 来缓解 DOX 诱导的氧化应激和细胞损伤。吸入的 TPCD NP 可以通过穿过肺上皮和内皮屏障在小鼠心脏中积累。相应地,吸入的 TPCD NP 有效地抑制了 DOX 诱导的小鼠心力衰竭。TTPCD NP 表现出相当增强的心脏靶向能力、细胞摄取效率和线粒体定位能力,从而增强了治疗效果。值得注意的是,TPCD NP 可以作为生物活性和 ROS 响应性纳米载体,与 Ac2-26 实现联合治疗,提供进一步增强的疗效。重要的是,吸入的 TPCD NP 在比有效剂量高 5 倍的剂量下显示出良好的安全性。纳米颗粒的吸入给药是一种有效、安全和非侵入性的策略,可用于靶向治疗心脏病。基于 TPCD NP 的纳米疗法是治疗心力衰竭和其他与氧化应激相关的急性/慢性心脏病的有前途的药物。